Zacks Investment Research Lowers Augmedix (OTCMKTS:AUGX) to Sell

Zacks Investment Research downgraded shares of Augmedix (OTCMKTS:AUGXGet Rating) from a hold rating to a sell rating in a research note issued to investors on Wednesday morning, Zacks.com reports.

According to Zacks, “Augmedix Inc. is a provider of remote medical documentation and live clinical support. Augmedix Inc. is based in SAN FRANCISCO, Calif. “

Several other equities analysts also recently weighed in on AUGX. Lake Street Capital began coverage on shares of Augmedix in a research note on Monday, March 7th. They issued a buy rating and a $6.00 target price for the company. Maxim Group initiated coverage on shares of Augmedix in a research report on Friday, January 21st. They issued a buy rating and a $6.00 price objective for the company. One analyst has rated the stock with a sell rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, Augmedix currently has an average rating of Buy and an average price target of $6.55.

AUGX opened at $2.12 on Wednesday. The company has a current ratio of 3.60, a quick ratio of 3.60 and a debt-to-equity ratio of 0.56. The firm has a 50-day moving average price of $2.70 and a 200-day moving average price of $3.05. Augmedix has a twelve month low of $2.00 and a twelve month high of $6.22.

Augmedix (OTCMKTS:AUGXGet Rating) last posted its earnings results on Wednesday, March 30th. The company reported ($0.16) earnings per share for the quarter. The business had revenue of $6.58 million during the quarter. Augmedix had a negative return on equity of 659.07% and a negative net margin of 80.54%. Equities research analysts anticipate that Augmedix will post -0.62 EPS for the current fiscal year.

Several hedge funds have recently added to or reduced their stakes in AUGX. Redmile Group LLC bought a new stake in Augmedix during the fourth quarter valued at approximately $45,298,000. DCM International VI Ltd. bought a new stake in Augmedix during the fourth quarter valued at approximately $13,980,000. American Financial Group Inc. bought a new stake in Augmedix during the fourth quarter valued at approximately $1,575,000. Perkins Capital Management Inc. bought a new stake in Augmedix during the fourth quarter valued at approximately $1,351,000. Finally, Geode Capital Management LLC bought a new stake in Augmedix during the fourth quarter valued at approximately $342,000. Institutional investors own 59.03% of the company’s stock.

About Augmedix (Get Rating)

Augmedix, Inc provides remote medical documentation solutions and live clinical support services in the United States. Its platform offers Augmedix Live and Augmedix Notes solutions that provide pre-visit documentation, such as pre-charting and digitization of previous records/patient history; during-visit documentation, including medical notes, care gap reminders, HCC reminders, and after-visit summaries; and post-visit documentation consisting of coding, orders, and referrals.

Recommended Stories

Get a free copy of the Zacks research report on Augmedix (AUGX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Augmedix (OTCMKTS:AUGX)

Receive News & Ratings for Augmedix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Augmedix and related companies with MarketBeat.com's FREE daily email newsletter.